Monupiravir (EIDD-2801) is an innovative antiviral drug. It is also known as EIDD-2801, is administered orally.
In the Cat FIP treatment, an antiviral drug known as Molnupiravir has entered the market. The pharmacokinetics of Molnupiravir is differ significantly from GS-441524, because of this, Molnupiravir must be administered twice daily.
The recommended dosage of EIDD-2801 tablets is 10 mg per kg of body weight, every 12 hours. The content is 40mg per tablets, if you cat is 3kg to 4 cat, take 1 tablet one time, twice per day.
Although this dosage seems similar to GS-441524, the key distinction lies in the dosing interval. Molnupiravir is administered every 12 hours, whereas GS-441524 is once every 24 hours.
Molnupiravir is often used in conjunction with GS-441524 or as an alternative solution.
Technical Support: We provide professional guidance on product information, mechanism of action, and application scope.
Documentation Support: COA, MSDS, and relevant technical documents are available.
Quality Assurance: Each batch manufactured under strict quality control.
Logistics Support: Secure packaging and reliable international shipping solutions.
Q1: What is Molnupiravir (EIDD-2801)?
Molnupiravir also called EIDD-2801, it is an antiviral nucleoside analog originally developed for the treatment of RNA virus infections. It can induce lethal mutations in viral RNA, preventing effective viral replication.
Q2: What disease is Molnupiravir used for in cats?
Molnupiravir is used in the treatment of FIP, which is a fatal disease caused by a mutated feline coronavirus.
Q3: What is the difference between Molnupiravir and GS-441524?
GS-441524 directly inhibits viral RNA synthesis, and Molnupiravir causes lethal mutations in the viral genome during replication. Because of their different mechanisms, they are often used together during treatment.
